ARCHIVES

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

This article is from The Cancer Letter archive.

Vol. 26 No. 11 | November 28, 2003

Download PDF Visit The Full Archive

Related Articles

O’Leary Leads RPCI’s OR;

February 8, 2002

Report Urges Changes To Cut Activation Times For NCI Phase III Trials.

April 9, 2010

In Brief: BRI Gets New FCRF Basic Research Contract; Senate Subcommittee Less Generous Than House

October 2, 1987

Community Cancer Center Group Formed to Deal With “Toad-Like Pace Of NCI,” Other Problems

June 7, 1974

Professional Societies: ONS To Study Trends In Health Economics Affecting Nursing

October 4, 1996

Interview: Extramural Programs Need Coordination, Klausner Says

July 25, 1997